Lymphangitis medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Lymphangitis most often | Lymphangitis most often is an acute complication following an extension from the skin infection with the potential of a systemic spread. It has to be promptly treated with appropriate antibiotics along with analgesics, anti-inflammatory medications, warm and moist compresses. Certain conditions like nodular lymphagitis that is complicated by abscess and lymphedema with significant lymphatic obstruction may require surgical intervention. | ||
==Principles of Therapy== | ==Principles of Therapy== | ||
==Therapy Based on Clinical Form== | |||
===Acute Lymphangitis=== | |||
====Empiric Therapy==== | |||
<SMALL><font color="#FF4C4C">'''▸ Click on the following categories to expand treatment regimens.'''</font><ref name="pmid23466022">{{cite journal| author=Moran GJ, Abrahamian FM, Lovecchio F, Talan DA| title=Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. | journal=J Emerg Med | year= 2013 | volume= 44 | issue= 6 | pages= e397-412 | pmid=23466022 | doi=10.1016/j.jemermed.2012.11.050 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23466022 }} </ref> | |||
{| | |||
| valign=top | | |||
<div style="border-radius: 5px 5px 0 0; border: solid 1px #20538D; border-bottom: 0px; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #A1BCDD; text-align: center;"> | |||
<font color="#FFF"> | |||
'''Acute Lymphangitis''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Mild - Moderate''' | |||
</font> | |||
</div> | |||
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Severe''' | |||
</font> | |||
</div> | |||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table01" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Mild - Moderate}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Penicillin V]] 500 mg PO q6h''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Life-Threatening Penicillin Allergies''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR> ▸'''''[[Vancomycin]] 15-20 mg/kg IV q8-12h''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected MSSA''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Dicloxacillin]] 500 mg PO q6h'''''<BR> OR <BR> ▸'''''[[Cephalexin]] 500 mg PO q6h'''''<BR> OR <BR> ▸'''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR> ▸ '''''[[Erythromycin]] 500 mg PO q6h''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected MRSA''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] 15-20 mg/kg IV q8-12h'''''<BR> OR <BR> ▸'''''[[Linezolid]] 600 mg IV/PO q12h'''''<BR> OR <BR> ▸'''''[[Daptomycin]] 4mg/kg IV q24h '''''<BR> OR <BR> ▸'''''[[Clindamycin]] 600 mg IV/PO q8h'''''<BR> OR <BR> ▸'''''[[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸'''''[[Minocycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸'''''[[TMP-SMX]] 8-12 mg/kg PO q12h/IV q6h''''' | |||
|- | |||
|} | |||
|} | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table02" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Severe}} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Penicillin G]] 2-4 MU IV q4-6h''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Life-Threatening Penicillin Allergies''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR> ▸'''''[[Vancomycin]] 15-20 mg/kg IV q8-12h''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected MSSA''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Dicloxacillin]] 500 mg PO q6h'''''<BR> OR <BR> ▸'''''[[Cephalexin]] 500 mg PO q6h'''''<BR> OR <BR> ▸'''''[[Clindamycin]] 300-450 mg PO q8h'''''<BR> OR <BR> ▸ '''''[[Erythromycin]] 500 mg PO q6h''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''For Suspected MRSA''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Vancomycin]] 15-20 mg/kg IV q8-12h'''''<BR> OR <BR> ▸'''''[[Linezolid]] 600 mg IV/PO q12h'''''<BR> OR <BR> ▸'''''[[Daptomycin]] 4mg/kg IV q24h '''''<BR> OR <BR> ▸'''''[[Clindamycin]] 600 mg IV/PO q8h'''''<BR> OR <BR> ▸'''''[[Doxycycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸'''''[[Minocycline]] 100 mg PO q12h'''''<BR> OR <BR> ▸'''''[[TMP-SMX]] 8-12 mg/kg PO q12h/IV q6h''''' | |||
|- | |||
|} | |||
|} | |||
|} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Inflammations]] | [[Category:Inflammations]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Signs and symptoms]] | [[Category:Signs and symptoms]] | ||
Revision as of 22:49, 30 May 2014
Lymphangitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Lymphangitis medical therapy On the Web |
American Roentgen Ray Society Images of Lymphangitis medical therapy |
Risk calculators and risk factors for Lymphangitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2]
Overview
Lymphangitis most often is an acute complication following an extension from the skin infection with the potential of a systemic spread. It has to be promptly treated with appropriate antibiotics along with analgesics, anti-inflammatory medications, warm and moist compresses. Certain conditions like nodular lymphagitis that is complicated by abscess and lymphedema with significant lymphatic obstruction may require surgical intervention.
Principles of Therapy
Therapy Based on Clinical Form
Acute Lymphangitis
Empiric Therapy
▸ Click on the following categories to expand treatment regimens.[1]
Acute Lymphangitis ▸ Mild - Moderate ▸ Severe |
|
References
- ↑ Moran GJ, Abrahamian FM, Lovecchio F, Talan DA (2013). "Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines". J Emerg Med. 44 (6): e397–412. doi:10.1016/j.jemermed.2012.11.050. PMID 23466022.